Sagimet Biosciences (SGMT) Common Equity (2023 - 2024)
Historic Common Equity for Sagimet Biosciences (SGMT) over the last 2 years, with Q3 2024 value amounting to $170.7 million.
- Sagimet Biosciences' Common Equity rose 7438.88% to $170.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $170.7 million, marking a year-over-year increase of 7438.88%. This contributed to the annual value of $91.1 million for FY2023, which is N/A changed from last year.
- According to the latest figures from Q3 2024, Sagimet Biosciences' Common Equity is $170.7 million, which was up 7438.88% from $183.3 million recorded in Q2 2024.
- Over the past 5 years, Sagimet Biosciences' Common Equity peaked at $190.0 million during Q1 2024, and registered a low of -$198.4 million during Q2 2023.